Leveraging electrochemical sensors to improve efficiency of cancer detection

Electrochemical biosensors have emerged as a promising technology for cancer detection due to their high sensitivity, rapid response, low cost, and capability for non-invasive detection. Recent advances in nanomaterials like nanoparticles, graphene, and nanowires have enhanced sensor performance to allow for cancer biomarker detection, like circulating tumor cells, nucleic acids, proteins and metabolites, at ultra-low concentrations. However, several challenges need to be addressed before electrochemical biosensors can be clinically implemented. These include improving sensor selectivity in complex biological media, device miniaturization for implantable applications, integration with data analytics, handling biomarker variability, and navigating regulatory approval. This editorial critically examines the prospects of electrochemical biosensors for efficient, low-cost and minimally invasive cancer screening. We discuss recent developments in nanotechnology, microfabrication, electronics integration, multiplexing, and machine learning that can help realize the potential of these sensors. However, significant interdisciplinary efforts among researchers, clinicians, regulators and the healthcare industry are still needed to tackle limitations in selectivity, size constraints, data interpretation, biomarker validation, toxicity and commercial translation. With committed resources and pragmatic strategies, electrochemical biosensors could enable routine early cancer detection and dramatically reduce the global cancer burden.